Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder

NCT ID: NCT05266716

Last Updated: 2022-03-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 79 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-18
• Study Completion Date: 2022-01-07

Brief Summary

The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® "app") as part of the Affect program of treatment for methamphetamine-primary stimulant use disorder. The study also will identify elements of the Affect app that enhance engagement of participants in the study toward the goal of improving patient outcomes, including reduction/cessation of stimulant use.

Detailed Description

The research project is a single-group observational demonstration study to assess the clinical utility of a digital therapeutic technology (the Affect app) in terms of participant acceptance and the app's ability to enhance retention in the Affect program of services for the treatment of individuals with meth-primary stimulant use disorder (MUD). Measures of reduction and/or cessation of methamphetamine use will be assessed by saliva drug tests at least twice weekly during each participant's 8-week involvement in the program, at end of treatment, and via self-report at follow-up points at 1, 3, and 6 months after completion of the program. The app-based program will involve the same services for study participants as would occur regardless of the research, being a standard of care for MUD. The intervention phase of the study will be completed within approximately four months, with follow-ups of the final participants occurring approximately six months after the end of the intervention phase.

Conditions

Methamphetamine Abuse

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Primary Arm

The study will involve a total of approximately 48 individuals enrolled during a six-week period as participants in the field test of the Affect digital therapeutic platform

Group Type: EXPERIMENTAL

Affect Methamphetamine Treatment Program

Intervention Type: BEHAVIORAL

Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.

Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change.

Interventions

Affect Methamphetamine Treatment Program

Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.

Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

1. Be 18 years of age or older;

2. Have methamphetamine use disorder (MUD) or documented high-risk methamphetamine use history, confirmed by DSM-5 criteria for stimulant use disorder, methamphetamine type;

3. Have stated interest in reducing and/or stopping methamphetamine use;

4. Have and be able to use a smartphone and agree to download and use the Affect app as part of treatment and study-related procedures;

5. Have a health insurance plan (or Medicaid) to ensure that participants have access to medical care if needed;

6. Be English speaking and have reading capacity sufficient to understand explanations of study procedures and the informed consent to participate;

7. Be a California resident with a mailing address or P.O. Box

8. Be able to freely give informed consent and be willing to electronically sign the digital informed consent to participate in the study;

9. Be willing to comply with study procedures, including use of the Affect app consistent with the study protocol and therapeutic activities.

Exclusion Criteria

Individuals will be precluded from enrolling in the study if they endorse (or if there is documentation of) any of following conditions. Already enrolled participants will be withdrawn from study participation upon emergence of any excluded condition (except pregnancy):

1. Serious medical diagnoses (e.g., seizure, stroke, heart disease);

2. Serious mental illness (e.g., schizophrenia, bipolar, active suicidality);

3. Moderate- to severe-level opioid use disorder or alcohol use disorder;

4. Pregnancy;

5. Have been in a prior study of pharmacological or behavioral treatment for MUD within 6 months of study consent;

6. Be concurrently receiving other behavioral or pharmacological services for treatment of MUD;

7. Have pending legal action or other situation that could inhibit consistent participation in the study or in study activities.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Affect Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Zito, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Affect Therapeutics

New York, New York, United States

Countries

United States

Provided Documents

Document Type: Informed Consent Form

View Document

Other Identifiers

Methamphetamine Field Study

Identifier Type: -

Identifier Source: org_study_id